Eupraxia Pharmaceuticals is trading 5.48% higher at $8.76, amid company-reported Phase 1b/2a RESOLVE trial results.
- On September 30, 2026, 64% (9 of 14) patients remained in clinical remission 52 weeks after one EP-104GI administration; 66% (2 of 3) in the highest-dose cohort maintained remission.
- The company also reported histologic improvements and favorable tolerability. Shares closed at $8.30 on September 29; no trading-volume information or explicit statement linking the release to the share-price reaction was located.